INTELLIGENT BIO SOLUTIONS IN
INBSNASDAQTrading Snapshot
- Day Range
- $2.03 – $2.10
- 52-Week Range
- $1.52 – $24.90
- Volume
- $1.69B
- Avg Volume
- $1.55B
- Shares Outstanding
- 645,750
- Next Earnings
- Oct 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $1M
- P/E Ratio
- -0.2
- P/S Ratio
- 0.3x
- EPS (TTM)
- $-7.28
- Dividend Yield
- 0.00%
Why Investors Own INBS
- ✓High-growth profile — revenue up +14.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 64% gross margin and 23% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About INTELLIGENT BIO SOLUTIONS IN
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Intelligent Bio Solutions Completes Usability Study For Intelligent Fingerprinting Drug Screening System To Detect Opiate Codeine
Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the completion of its
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session. SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding shares is at
Intelligent Bio Solutions Resolves All Cybersecurity, Software-Related Review Items For Its Upcoming FDA Submission
Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it has addressed
Intelligent Bio Solutions Completes Precision Testing For Its Intelligent Fingerprinting Drug Screening System To Detect Opiate Codeine
Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the completion of